Medical Decision Analysis in Infectious Diseases

Overview

Journal Can J Infect Dis

Date 2007 Dec 27

PMID 18159308

Authors

U D Allen

Affiliations

Soon will be listed here.

Abstract

Medical decision analysis (MDA) has played an important role in assisting infectious disease physicians make decisions associated with varying levels of complexity. Clinicians are often uncomfortable with some aspects of MDA, particularly when utilities are used as outcome measures. However, as the present paper outlines, MDA may use other outcome variables, including costs and disease complications. In this context, this explicit, reproducible analytic framework is an important tool in the area of infectious diseases, and is frequently applied to many situations, including cost effectiveness analyses, studies involving assessment of risks versus benefits of preventive and treatment strategies, and other situations. The objective of this paper is to assist infectious diseases clinicians to understand better the role of MDA in clinical practice. In this regard, the principles of MDA are reviewed and a common clinical example is used for illustrative purposes.

References

. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996; 45(22):468-80. View

Magid D, Schwartz B, Craft J, Schwartz J . Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med. 1992; 327(8):534-41. DOI: 10.1056/NEJM199208203270806. View

Allen U, Guerriere M, Read S, Detsky A . Percutaneous injuries among health care workers. The real value of human immunodeficiency virus testing of 'donor' blood. Arch Intern Med. 1991; 151(10):2033-40. DOI: 10.1001/archinte.151.10.2033. View

Plume S . Choices, chances, values. Ann Thorac Surg. 1992; 53(3):373. DOI: 10.1016/0003-4975(92)90253-z. View

. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Recomm Rep. 1990; 39(RR-1):1-14. View

Fineberg H . Decision trees: construction, uses, and limits. Bull Cancer. 1980; 67(4):395-404. View

Krahn M, Detsky A . Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making. 1993; 13(1):4-20. DOI: 10.1177/0272989X9301300103. View

Pauker S, Kassirer J . Decision analysis. N Engl J Med. 1987; 316(5):250-8. DOI: 10.1056/NEJM198701293160505. View

Allen U, Read S, Gafni A . Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: an economic evaluation. Clin Infect Dis. 1992; 14(4):822-30. DOI: 10.1093/clinids/14.4.822. View

10.

. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-7):1-33. View

11.

Randolph A, Hartshorn R, Washington A . Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol. 1996; 88(4 Pt 1):603-10. DOI: 10.1016/0029-7844(96)00261-x. View

12.

Lieu T, Fleisher G, Schwartz J . Cost-effectiveness of rapid latex agglutination testing and throat culture for streptococcal pharyngitis. Pediatrics. 1990; 85(3):246-56. View

13.

SCHWARTZ W . Sounding board. Decision Analysis: a look at the chief complaints. N Engl J Med. 1979; 300(10):556-9. DOI: 10.1056/NEJM197903083001011. View

14.

Detsky A . Decision analysis: what's the prognosis?. Ann Intern Med. 1987; 106(2):321-2. DOI: 10.7326/0003-4819-106-2-321. View

15.

Halpern M, Brown R, Drolet M, Sorensen S, Mandell L . Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada. Can J Infect Dis. 2012; 8(1):19-27. PMC: 3327332. DOI: 10.1155/1997/106462. View

16.

Torrance G . Utility approach to measuring health-related quality of life. J Chronic Dis. 1987; 40(6):593-603. DOI: 10.1016/0021-9681(87)90019-1. View